Methods
We reviewed the records of women with advanced CKD who had successfully completed parturition at Seoul St. Mary's Hospital between January 2012 and December 2014. The study included patients who conceived when their glomerular filtration rate (GFR) was severely reduced (GFR < 30 mL/min) and who maintained their pregnancy beyond the first trimester.
We evaluated the incidence of maternal and neonatal deaths, pregnancy-related complications, changes in dialysis prescriptions, and anemia management during pregnancy. A total of 5 women were included in the study.
From the hospital computer records, we obtained clinical information, including maternal age at conception and delivery, parity, primary renal disease, other underlying medical conditions, dialysis prescriptions, dose of erythropoietin (EPO) and iron therapy, and maternal and fetal outcomes. We also collected biochemical and hematologic data, including complete blood count, urea, creatinine, total protein, albumin, iron, total iron-binding capacity, and ferritin. Data are presented as the mean ± standard deviation or counts and percentages to the nearest 10th.
This study was approved by the Institutional Review Board of Seoul St. Mary's Hospital (KC15RISI0621).
Discussion
Although recent case series and systematic reviews have reported a trend toward improved pregnancy outcomes for patients with advanced CKD, in Korea, the pregnancy outcomes in these high-risk patients remain under-reported. Here, we present recent successful pregnancies in women with advanced CKD in the Seoul St. Mary's Hospital dialysis center.
Despite the small possibility of conception and maintenance of pregnancy faced by patients with CKD, in our center, 7 women with CKD successfully delivered newborns. Five of these patients had a GFR less than 15 mL/min/1.73 m
2 and were included in our study. Four of these patients were treated with HD for an average duration of 70.2 ± 35.2 months before conception–a far lengthier preconception period of dialysis than reported by other studies
[7],
[8]. It was encouraging that these pregnancies in patients with advanced CKD resulted in 5 successful deliveries over a 3-year period at a single center.
Most likely, several factors contributed to these positive results. First, all our patients were in a good general health at the time of conception. For example, the average level of serum albumin, which was measured serially during prenatal care, was 4.1 ± 0.4 g/dL before pregnancy and was maintained above 3.0 g/dL by all patients throughout pregnancy. Because albumin is considered to be representative of a patient's nutritional and inflammatory status, we can assume that these women were able to achieve optimal dietary intake and an inflammation-free status before and during gestation. This most likely contributed to the successful occurrence and maintenance of their pregnancies.
Well-controlled blood pressure could be another contributing factor to successful conception and maintenance of pregnancy. Most patients with CKD have chronic hypertension and tend to require multidrug treatment. Moreover, patients who require multiple medications for blood pressure control or those whose hypertension is poorly controlled are at an increased risk of adverse pregnancy outcomes, including maternal morbidity and fetal loss
[9]. However, among our patients, one was normotensive and the others maintained their blood pressure under control with single, low-dose antihypertensive therapy. Before the development of pre-eclampsia, blood pressure was maintained below 130/80 mmHg for all patients during pregnancy. This maintenance of the maternal blood pressure may have helped to stabilize the fetoplacental circulation.
Technological improvements in dialysis and more intensive dialysis are also crucial contributors to these positive outcomes. To avoid excessive fluid loss and sudden changes in osmolarity, pregnant patients are recommended a high biocompatibility dialyzer with a lower surface area and increased time on dialysis
[2],
[3],
[7],
[10],
[11],
[12],
[13],
[14],
[15]. Frequent dialysis during pregnancy may allow for better and gentler fluid and blood pressure management, liberal fluid and diet intake, and greater reductions in the level of urea
[10]. In the present study, all 4 dialysis patients were treated with a high biocompatible dialyzer with a surface area of less than 1.5 m
2. Moreover, they received regular HD that was increased after pregnancy confirmation (from 11.0 ± 2.0 h/wk to 20.0 ± 5.7 h/wk), and the ultrafiltration dose was maintained at less than 2.0 kg/session. Although several review articles have suggested that increasing the frequency of HD after the second trimester to more than 5 sessions/wk might lead to better fetal outcomes, 1 patient in our center received only 3 sessions of HD/wk until delivery. Two years previously, she got sudden damage to kidney due to pre-eclampsia and increase in lupus activity during her first delivery. Although she was undergoing less frequent HD, her daily urine output was maintained at approximately 1,000 mL, which was sufficient to achieve a healthy status without significant volume overload, uremia, or electrolyte imbalance. During her second pregnancy 2 years later, we adjusted her HD frequency from semiweekly to 3 times a week and monitored her volume and biochemical status. This HD schedule was well tolerated and was maintained during the entire gestation. Ultimately, she delivered a healthy, term newborn. These findings suggest that, in pregnant patients with end-stage renal disease, the level to which the frequency of dialysis is increased should be individualized.
We used a well-accepted approach toward the management of anemia. During a healthy pregnancy, erythrocyte volume increases by an average of 450 mL, and vigorous erythropoiesis leads to a large requirement for iron. In uncomplicated pregnancies, iron supplementation of just 6–7 mg/d is sufficient to satisfy this requirement
[9]. However, because they are often deficient in EPO, pregnant women with advanced CKD require supplementation with both iron and EPO to maintain acceptable hematologic parameters. Pregnant women with CKD who are anemic have a higher risk of preterm labor
[2],
[16]. The use of high-dose EPO in combination with iron therapy has also been shown to eliminate the need for blood transfusions in such patients
[2],
[7],
[17],
[18],
[19]. In this study, 3 patients received an ESA at a higher dosage. The only predialytic patient began treatment with an ESA midtrimester. Although 1 patient received rather lower dosage of EPO during pregnancy, hematologic parameters were closely monitored in all patients, and the hemoglobin and hematocrit levels were largely maintained over 10.0 g/dL and 30%, respectively. No patient required a blood transfusion at any time during her pregnancy.
Finally, a multidisciplinary team approach that includes nephrologists, obstetricians, and neonatologists is likely to have a positive influence on pregnancy outcomes for women with CKD. Our active management of dialysis and anemia treatment was combined with frequent antenatal obstetric follow-up. In addition, newborns received immediate, intensive postnatal care. Pertinent patient information was shared among team members in advance, enabling the proper handling of adverse events, even in emergency situations. Although the majority of neonates were born prematurely, all were discharged from the hospital alive.
Nevertheless, similar to previous studies, there were several adverse outcomes. Renal dysfunction is known to increase the risk of pre-eclampsia. In one of the largest case series to date that included 52 pregnancies, Luders et al
[20] reported that pre-eclampsia was diagnosed in 10 (19.2%) patients and negatively affected the rate of successful deliveries. In our study, apart from 1 patient who had a normal spontaneous vaginal delivery, all patients had cesarean sections, with 3 women undergoing emergency operations due to pre-eclampsia. Although the patients delivered in a timely fashion before the development of eclampsia, one patient experienced hypermagnesemia-induced diplopia and vomiting during magnesium sulfate therapy for pre-eclampsia. In patients with advanced CKD who have difficulty regulating electrolyte balance, meticulous care is required when administering with intravenous magnesium for the management of pre-eclampsia.
The failure to achieve optimal pregnancy weight gain during pregnancy likely contributed to intrauterine growth restriction. Pregnant women are encouraged to gain at least 11–12 kg (0.36–0.45 kg/wk)
[9], and dialysis patients require a weight gain of approximately 0.5 kg/wk to avoid maternal hypotension and volume depletion
[10],
[18]. The patients in our study, however, gained an average of just 5.2 kg, which is lower than recommended and may explain why their babies were small for their GA. Based on the recommendations outlined in textbooks and review articles, a weight gain of 0.36–0.5 kg/wk may help to prevent preterm birth and fetal-growth restriction. In pregnant patients with advanced CKD, it is difficult to determine how much of the weight gain is because of excess fluid rather than pregnancy-associated weight gain. Nevertheless, these patients should be encouraged to achieve an optimal pregnancy weight gain with careful weekly examinations to look for signs of fluid overload.
Consistent with other studies, the incidence of suboptimal fetal outcomes remained high in women with advanced CKD, notwithstanding advances in obstetrical and neonatal care
[21]. In our investigation, all 5 newborns were small for their GA and 3 of them experienced various complications related to preterm delivery. Four newborns were admitted to the NICU, for an average of 81 days, and one of them was transferred to the neonatal care unit at another center on hospital Day 240. Although there was no neonatal death during hospitalization in our medical center, we do not have follow-up information about the newborn who was transferred to another medical center. Thus, we cannot exclude the possibility of an infant death.
Our study has several limitations. First, this is an observational study, and the number of patients included is too small to establish a causal relationship between kidney disease and adverse maternal and fetal outcomes. Second, we did not have objective data to evaluate the adequacy of dialysis or a body water-indexed clearance × time product (Kt/V). Nevertheless, this study is meaningful because it is the first report in Korea that includes 5 consecutive cases of pregnant patients with advanced CKD who achieved a successful pregnancy outcome. We hope that our experience will generate interest in these high-risk pregnancies and help to guide clinical management of similar patients.
In summary, our article describes successful pregnancy outcomes in 5 women with advanced CKD. Clearly, the small number of patients necessitates a larger scale observational study. Nevertheless, we cautiously conclude that these encouraging outcomes resulted from the maintenance of good general health before conception and intensive multidisciplinary management after pregnancy confirmation. The rate of neonatal complications is still high and remains to be addressed. We hope that our report will be helpful to health care providers in counseling and managing women with advanced CKD during pregnancy.